SARS-CoV-2 IgG antibodies in COVID-19 convalescent plasma and conventional plasma units.

ABSTRACT:

Background

The Association for the Advancement of Blood and Biotherapies guidelines recommend the use of high-titer COVID-19 convalescent plasma (CCP) for patients with SARS-CoV-2 at high risk of disease progression, including those who are immunocompromised. We hypothesized that conventional plasma units have comparable neutralizing antibody levels to CCP.

Study design and methods

Conventional plasma and CCP units were obtained from blood suppliers. Quantitatively measured antibodies to SARS-CoV-2 were assessed using the MesoScale Discovery multiplex electrochemiluminescence immunoassay. Binding antibody distributions were compared with Wilcoxon rank-sum tests. SARS-CoV-2 neutralizing antibodies were analyzed using the GeneScript ELISA-based neutralization assay. The propor

SUBMITTER: Sulaiman A 

PROVIDER: S-EPMC11925680 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature